MedPath

Exercise Training in Sarcoidosis (EXTRAS Study)

Not Applicable
Completed
Conditions
Sarcoidosis
Registration Number
NCT00099424
Lead Sponsor
University Hospital, Gasthuisberg
Brief Summary

Exercise intolerance and reduced health status have been found in patients with sarcoidosis and has been related to skeletal muscle weakness. The present researchers reason that skeletal muscle weakness is, at least in part, related to physical inactivity and therefore partially reversible following a structured exercise training program. Nevertheless, the effects of exercise training have never been studied in patients with sarcoidosis. Therefore, the present study is undertaken to explore the effects of exercise training in patients with sarcoidosis. A priori, the following hypotheses are formulated:

* A 12-week exercise training program improves health status, quality of life and exercise capacity in patients with sarcoidosis as compared to sarcoidosis patients without exercise intervention.

* A 12-week exercise training program improves skeletal muscle function and reduces complaints of anxiety and depression in patients with sarcoidosis as compared to sarcoidosis patients without exercise intervention.

* A 12-week exercise training program reduces circulating levels of inflammatory markers in patients with sarcoidosis as compared to sarcoidosis patients without exercise intervention.

Detailed Description

The EXTRAS study is a prospective, randomized, controlled, 24-week crossover clinical trial in which the participants are randomly assigned to receive 12 weeks of dynamic resistance and whole-body endurance exercises followed by 12 weeks without intervention or vice versa. Consenting participants will be assessed at baseline (before randomization, week 0) and at weeks 12 and 24.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Main diagnosis: previously diagnosed sarcoidosis according to the latest ATS/ERS/WASOG statement on sarcoidosis (AJRCCM 1999)
Exclusion Criteria
  • A history of neurosarcoidosis
  • Undergoing structured exercise training at the time of enrollment or in the preceding 6 months
  • Current participation in a pharmacological study
  • Cardiovascular abnormalities on the ECG during baseline peak exercise test
  • A 'normal' baseline peak oxygen uptake (≥90% of the predicted values) in combination with a 'normal' quadriceps peak torque or distance walked in 6 minutes

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
Health status: Medical Outcomes Study 36-Item Short-Form Health Survey
Disease-specific quality of life: Sarcoidosis Health Questionnaire
Peak exercise capacity: a symptom-limited peak exercise test on a cycle ergometer
Functional exercise capacity (I): a symptom-limited endurance cycling test at 70% of the achieved peak external load
Functional exercise capacity (II): the distance walked in 6 minutes
Secondary Outcome Measures
NameTimeMethod
Pulmonary function: forced vital capacity and transfer factor for carbon monoxide
Muscle function: isometric quadriceps femoris muscle peak torque
Systemic inflammation: circulating levels of IL-2, sIL-2r, IL-6, IL-8, TNF-alpha, sTNFR-p55, sTNFR-p75
Anxiety and depression: Hospital Anxiety and Depression Scale
Health-related quality of life (I): Chronic Respiratory Disease Questionnaire
Health-related quality of life (II): St. George's Respiratory Questionnaire

Trial Locations

Locations (1)

University Hospital Leuven

🇧🇪

Leuven, Vlaams-Brabant, Belgium

© Copyright 2025. All Rights Reserved by MedPath